Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
19.16
-0.06 (-0.31%)
May 30, 2025, 11:44 AM CST
SHE:002932 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 350.06 | 749.49 | 10,530 | 2,830 | 959.1 | Upgrade
|
Other Revenue | - | 0.05 | - | - | - | Upgrade
|
Revenue | 350.06 | 749.54 | 10,530 | 2,830 | 959.1 | Upgrade
|
Revenue Growth (YoY) | -53.30% | -92.88% | 272.12% | 195.05% | 429.43% | Upgrade
|
Cost of Revenue | 161.41 | 309.72 | 3,992 | 707.41 | 209.97 | Upgrade
|
Gross Profit | 188.65 | 439.82 | 6,538 | 2,122 | 749.13 | Upgrade
|
Selling, General & Admin | 169.61 | 218.97 | 591.45 | 273.23 | 122.84 | Upgrade
|
Research & Development | 109.55 | 141.42 | 388.36 | 132.74 | 69.93 | Upgrade
|
Other Operating Expenses | -75.84 | 1.41 | 59.79 | 12.8 | 5.53 | Upgrade
|
Operating Expenses | 203.33 | 446.93 | 1,403 | 439.59 | 204.57 | Upgrade
|
Operating Income | -14.67 | -7.11 | 5,135 | 1,683 | 544.56 | Upgrade
|
Interest Expense | - | -10.5 | -3.42 | -2.11 | -0.65 | Upgrade
|
Interest & Investment Income | 133.7 | 124.94 | 52.85 | 12.36 | 6.18 | Upgrade
|
Currency Exchange Gain (Loss) | - | 1.22 | 21.52 | -3.13 | -1.44 | Upgrade
|
Other Non Operating Income (Expenses) | -3.22 | 4.88 | -7.46 | -1.08 | -0.39 | Upgrade
|
EBT Excluding Unusual Items | 115.81 | 113.42 | 5,199 | 1,689 | 548.26 | Upgrade
|
Gain (Loss) on Sale of Investments | 1.74 | 4.59 | 2.76 | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | 1.79 | 0.31 | 0.01 | - | 0.15 | Upgrade
|
Asset Writedown | -86.92 | -38.02 | -147.03 | - | - | Upgrade
|
Other Unusual Items | - | 59.59 | 22.02 | 5.69 | 8.29 | Upgrade
|
Pretax Income | 32.42 | 139.89 | 5,076 | 1,695 | 556.7 | Upgrade
|
Income Tax Expense | 5.85 | 70.67 | 695.84 | 247.87 | 81.07 | Upgrade
|
Earnings From Continuing Operations | 26.56 | 69.22 | 4,381 | 1,447 | 475.63 | Upgrade
|
Minority Interest in Earnings | 47.95 | 5.71 | -172.06 | -33.46 | -6.7 | Upgrade
|
Net Income | 74.52 | 74.93 | 4,208 | 1,413 | 468.93 | Upgrade
|
Net Income to Common | 74.52 | 74.93 | 4,208 | 1,413 | 468.93 | Upgrade
|
Net Income Growth | -0.54% | -98.22% | 197.79% | 201.37% | 1029.25% | Upgrade
|
Shares Outstanding (Basic) | 226 | 227 | 228 | 212 | 209 | Upgrade
|
Shares Outstanding (Diluted) | 226 | 227 | 230 | 212 | 209 | Upgrade
|
Shares Change (YoY) | -0.54% | -1.22% | 8.61% | 1.43% | 0.23% | Upgrade
|
EPS (Basic) | 0.33 | 0.33 | 18.46 | 6.68 | 2.25 | Upgrade
|
EPS (Diluted) | 0.33 | 0.33 | 18.31 | 6.68 | 2.25 | Upgrade
|
EPS Growth | - | -98.20% | 174.19% | 197.11% | 1026.62% | Upgrade
|
Free Cash Flow | -269.81 | 282.52 | 3,699 | 1,023 | 331.4 | Upgrade
|
Free Cash Flow Per Share | -1.20 | 1.24 | 16.09 | 4.84 | 1.59 | Upgrade
|
Dividend Per Share | - | 0.120 | 3.490 | 2.027 | 0.643 | Upgrade
|
Dividend Growth | - | -96.56% | 72.18% | 214.98% | 1898.45% | Upgrade
|
Gross Margin | 53.89% | 58.68% | 62.09% | 75.00% | 78.11% | Upgrade
|
Operating Margin | -4.19% | -0.95% | 48.77% | 59.47% | 56.78% | Upgrade
|
Profit Margin | 21.29% | 10.00% | 39.97% | 49.94% | 48.89% | Upgrade
|
Free Cash Flow Margin | -77.08% | 37.69% | 35.13% | 36.17% | 34.55% | Upgrade
|
EBITDA | 42.38 | 59.3 | 5,180 | 1,704 | 561.8 | Upgrade
|
EBITDA Margin | 12.11% | 7.91% | 49.19% | 60.22% | 58.58% | Upgrade
|
D&A For EBITDA | 57.05 | 66.41 | 45.04 | 21.28 | 17.24 | Upgrade
|
EBIT | -14.67 | -7.11 | 5,135 | 1,683 | 544.56 | Upgrade
|
EBIT Margin | -4.19% | -0.95% | 48.77% | 59.47% | 56.78% | Upgrade
|
Effective Tax Rate | 18.05% | 50.52% | 13.71% | 14.63% | 14.56% | Upgrade
|
Revenue as Reported | - | 749.54 | 10,530 | 2,830 | 959.1 | Upgrade
|
Advertising Expenses | - | 12.13 | 56.66 | 23.94 | 6.97 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.